GM1 Gangliosidosis Market Growth Outlook: Trends, Market Size, and Opportunities Over the Next Decade
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Major Innovations Are Driving the Accelerated Growth of the GM1 Gangliosidosis Market?
The increasing use of gene therapy is set to drive the growth of the GM1 gangliosidosis market. Gene therapy is a medical approach that involves altering or replacing genes within an individual’s cells to treat or prevent diseases. The increasing adoption of gene therapy is driven by advancements in genetic research, better treatment outcomes for previously untreatable conditions, and greater regulatory support for innovative therapies. Gene therapy for GM1 gangliosidosis involves introducing a functional copy of the defective GLB1 gene into patient cells to restore β-galactosidase enzyme activity and reduce the buildup of toxic substrates. For instance, in April 2024, the American Society of Gene & Cell Therapy, a US-based non-profit organization, reported that the number of phase III gene therapy clinical trials increased by 10% in the fourth quarter, marking the first rise since the third quarter of 2022. Consequently, the increasing adoption of gene therapy is driving the growth of the GM1 gangliosidosis market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp
#What is the Growth Potential of the GM1 Gangliosidosis Market, and How Will It Perform by 2034?
The GM1 gangliosidosis market has expanded rapidly, growing from $0.51 billion in 2024 to $0.57 billion in 2025 at a CAGR of 11.4%. Growth in this segment is driven by an increasing number of GM1 gangliosidosis patients, heightened focus on rare diseases, greater awareness, patient-centric research initiatives, and an increased emphasis on early intervention.
The GM1 gangliosidosis market is projected to expand rapidly, reaching $0.87 billion by 2029 at a CAGR of 11.1%. The expected growth is attributed to rising cases of GM1 gangliosidosis, increasing occurrences of lysosomal storage disorders, a surge in clinical trials, a greater focus on gene therapy and gene editing, an increase in personalized and precision medicine, and wider adoption of genetic screening programs. Key trends include breakthroughs in gene-editing technologies, integration of digital tools in healthcare, advancements in diagnostic methods, the development of advanced formulations, and improvements in genetic therapies.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21194
What Are the Most Significant Market Trends Transforming theGM1 Gangliosidosis Market?
Major companies in the GM1 gangliosidosis market are focusing on strategic partnerships to advance gene therapy development. These partnerships combine resources and expertise to accelerate research and clinical trials. In October 2024, GEMMA Biotherapeutics Inc., a US-based biotechnology company, partnered with the Oswaldo Cruz Foundation (Fiocruz) in Brazil to develop gene therapies for rare diseases, including GM1 gangliosidosis. This collaboration, with up to $100 million in funding, aims to bring advanced therapies to public healthcare systems in Brazil, democratizing access to treatments that were previously limited to wealthier populations.
What Are the Top Market Players Propelling the Growth of theGM1 Gangliosidosis Industry?
Major companies operating in the GM1 gangliosidosis market are Pfizer Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc., CRISPR Therapeutics AG, REGENXBIO Inc., Passage Bio Inc., Orchard Therapeutics plc, AVROBIO Inc., uniQure N.V., GEMMA Biotherapeutics Inc., Lysogene S.A., AZAFAROS B.V., BioStrategies LC, Sio Gene Therapies Inc., Gain Therapeutics Inc., Dorphan S.A., bluebird bio Inc., Axovant Gene Therapies Ltd., SphinCS GmbH.
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report
Which Primary Segments of the GM1 Gangliosidosis Market Are Driving Growth and Industry Transformations?
The GM1 gangliosidosis market covered in this report is segmented –
1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis
2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy
3) By End-User: Research Institutes, Hospitals, Other End-Users
Subsegments:
1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset
2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset
3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=21194&type=smp
Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the GM1 Gangliosidosis Market?# Market?
North America was the largest region in the GM1 gangliosidosis market in 2024. The regions covered in the GM1 gangliosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global GM1 Gangliosidosis Market 2025, By The Business Research Company:
Osteoporosis Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/osteoporosis-treatment-global-market-report
Postmenopausal Osteoporosis Treatment Global Market Report 2025
Next-Generation Antibody Therapeutics Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
